蓝苓降脂颗粒对高脂血症脾虚痰瘀阻滞证临床疗效的影响

发布时间：2019-03-18 18:15

【摘要】：目的:初步评价蓝苓降脂颗粒治疗高脂血症(脾虚痰瘀阻滞证)的临床疗效。方法:以湖南中医药大学第二附属医院心血管科筛选的60例高脂血症患者为研究对象,中医辨证为脾虚痰瘀阻滞证,随机分为治疗组(蓝苓降脂颗粒组)30例及对照组(血脂康组)30例,以阳性对照双盲双模拟的试验设计方式,治疗组予以蓝苓降脂颗粒一次1包,一日2次+模拟血脂康胶囊一次2粒,一日2次,对照组予以血脂康胶囊一次2粒,一日2次+模拟蓝苓降脂颗粒,一次1包,一日2次,治疗周期均为4周。分别观察治疗前后两组患者中医症候积分、血脂水平改善情况、C反应蛋白水平、患者总有效率等变化,通过统计得出研究结果,以评价分析蓝苓降脂颗粒的临床疗效及安全性。结果:在中医症候方面,治疗组总有效率93.3%优于对照组总有效66.6%,说明治疗组治疗高脂血症在改善中医症候方面有明显疗效(P0.05)。血脂水平前后比较,两组患者组内比较降低TC、TG、LDL-C和升高HDL-C效果均显著(P0.01)。两组患者组间比较,治疗前TC、TG、LDL-C、HDL-C无统计学意义(P0.05);治疗后两组降低TC、TG水平疗效相当,无统计学意义(P0.05),治疗组降低LDL-C和升高HDL-C疗效优于对照组(P0.05)。结果说明治疗组治疗高脂血症在降低低密度脂蛋白和升高高密度脂蛋白方面疗效显著。CRP水平前后比较,两组组内及组间比较,差异均有统计学意义(P0.05),说明治疗组对CRP水平改善程度优于对照组。临床观察期间,两组均未发现严重不良反应事件。结论:蓝苓降脂颗粒治疗高脂血症脾虚痰瘀阻滞证患者,具有良好的调脂、改善中医症候积分及有效降低C-反应蛋白水平,副作用少,安全可靠。
[Abstract]:Objective: to evaluate the clinical efficacy of Lanling Jiangzhi granule in the treatment of hyperlipidemia (syndrome of spleen deficiency and phlegm stasis). Methods: 60 cases of hyperlipidemia were selected from the Department of Cardiovascular Medicine of the second affiliated Hospital of Hunan University of traditional Chinese Medicine, and the syndrome differentiation of TCM was syndrome of spleen deficiency and phlegm stasis. They were randomly divided into treatment group (Luling Jiangzhi granule group, n = 30) and control group (Xuezhikang group, n = 30). Xuezhikang capsule was simulated twice a day and twice a day. The control group was given Xuezhikang capsule 2 tablets once a day, twice a day to simulate Luling Jiangzhi granule, 1 packet once, twice a day, and the treatment period was 4 weeks. Before and after treatment, the TCM symptom integral, the improvement of blood lipid level, the level of C-reactive protein and the total effective rate of the two groups were observed, and the results of the study were obtained by statistics. To evaluate the clinical efficacy and safety of Lanling Jiangzhi granules. Results: in terms of TCM symptoms, the total effective rate of the treatment group was 93.3% higher than that of the control group, which indicated that the treatment group had obvious curative effect in improving the TCM syndrome of hyperlipidemia (P0.05). Compared with before and after blood lipid level, the effect of decreasing TC,TG,LDL-C and increasing HDL-C in the two groups was significant (P0.01). There was no significant difference in TC,TG,LDL-C,HDL-C before treatment between the two groups (P0.05). There was no significant difference between the two groups in reducing TC,TG level after treatment (P0.05). The therapeutic effect of treatment group was better than that of control group in reducing LDL-C and increasing HDL-C (P0.05). The results showed that the treatment group had significant effect on lowering low density lipoprotein and increasing high density lipoprotein. Compared with before and after CRP level, the difference was statistically significant between the two groups (P0.05). The results showed that the improvement of CRP level in the treatment group was better than that in the control group. During the clinical observation, no serious adverse reaction events were found in both groups. Conclusion: Lanling Jiangzhi granule in treating hyperlipidemia patients with spleen deficiency, phlegm and blood stasis syndrome has good lipid regulation, improve TCM syndrome integral and effectively reduce the level of C-reactive protein, with less side effects, safe and reliable. [WT5 "HZ] conclusion: [WT5" BZ] [WT5 "BZ]
【学位授予单位】：湖南中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【参考文献】